BB
SAGE

BB Biotech’s Sage Therapeutics SAGE Stock Holding History

BB Biotech’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$219M Hold
1,375,229
– – 5.5% 5
2018
Q4 		$132M Buy
1,375,229
+303,856
+28% +$34.8M 4.22% 8
2018
Q3 		$151M Hold
1,071,373
– – 4% 8
2018
Q2 		$168M Buy
1,071,373
+68,934
+7% +$10.8M 4.84% 9
2018
Q1 		$161M Sell
1,002,439
-40,000
-4% -$6.79M 4.46% 11
2017
Q4 		$172M Sell
1,042,439
-50,000
-5% -$4.85M 4.84% 9
2017
Q3 		$68.1M Buy
1,092,439
+185,000
+20% +$14.5M 1.88% 16
2017
Q2 		$72.3M Sell
907,439
-65,000
-7% -$4.7M 2.21% 14
2017
Q1 		$69.1M Sell
972,439
-50,000
-5% -$2.93M 2.26% 13
2016
Q4 		$52.2M Hold
1,022,439
– – 1.93% 13
2016
Q3 		$47.1M Buy
1,022,439
+171,800
+20% +$6.99M 1.66% 16
2016
Q2 		$25.6M Buy
850,639
+16,976
+2% +$566K 1.01% 22
2016
Q1 		$26.7M Buy
833,663
+125,000
+18% +$4.4M 1.06% 21
2015
Q4 		$41.3M Buy
+708,663
New +$35.1M 1.16% 21

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BB Biotech's SAGE Position: Q1 2019 in Review

BB Biotech held its Sage Therapeutics (SAGE) position steady in Q1 2019 at 1,375,229 shares worth $219M. The position accounts for 5.5% of the portfolio, ranked #5.

BB Biotech first reported a position in SAGE in Q4 2015 and has held it in 14 quarters since. 267 funds tracked by Wall St. Rank hold SAGE as of Q1 2019.

  • BB Biotech held 1,375,229 shares of Sage Therapeutics worth $219M as of Q1 2019.
  • BB Biotech left its Sage Therapeutics share count unchanged in Q1 2019.
  • Sage Therapeutics made up 5.5% of BB Biotech's portfolio in Q1 2019, its #5 holding.
  • BB Biotech first reported a position in Sage Therapeutics in Q4 2015 and has held it in 14 quarters since.
  • 267 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2019.

Based on BB Biotech's 13F filing for Q1 2019, filed 13 May 2019.